Email this article TARGET THERAPY FOR NON-SMALL CELL LUNG CANCER: COMPLETE RESPONSE TO CRIZOTINIB
- Authors: Gordeeva O.O.1, Meshcheryakov A.A1, Meshcheryakova N.A1
-
Affiliations:
- N.N. Blokhin Cancer Research Center
- Issue: Vol 24, No 1-2 (2019)
- Pages: 27-31
- Section: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/42968
- DOI: https://doi.org/10.18821/1028-9984-2019-24-1-2-27-31
- ID: 42968
Cite item
Full Text
Abstract
In this article we demonstrate a clinical case of young patient with non-small lung cancer with ALK-translocation treated with crizotinib in the first line of therapy. This approach was associated with complete response and acceptable toxicity.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Olga O. Gordeeva
N.N. Blokhin Cancer Research Center
Email: helga.stolz@yandex.ru
Medical Oncologist, chemotherapy department #3, N.N.Blokhin NMRCO, 115478, Moscow, Russian Federation 115478, Moscow, Russian Federation
A. A Meshcheryakov
N.N. Blokhin Cancer Research Center115478, Moscow, Russian Federation
N. A Meshcheryakova
N.N. Blokhin Cancer Research Center115478, Moscow, Russian Federation
References
- Arteaga C.L. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin. Oncol. 2002; 29: 3-9.
- Paez J.G., Janne P.A., Lee J.C. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (Wash D C). 2004; 304: 1497-500
- Soda M., Choi Y.L., Enomoto M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448 (7153): 561-6.
- Alice T. Shaw, Beow Y. Yeap, Mari Mino-Kenudson, et al. Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK. J Clin. Oncol. 27: 4 247-53.
- Ming Sound Tsao, Fred R. Hirsch, Yasushi Yatabe. IASLC atlas of ALK testing in lung cancer. 2013.
- Benjamin J. Solomon et al. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. N. Engl. J. Med. 2014; 371: 2167-77.
- Юкальчук Д.Ю. и др. Применение кризотиниба в терапии ALK-позитивного немелкоклеточного рака лёгкого. Эффективная фармакотерапия. Онкология, гематология и радиология. Спецвыпуск «Рак: расширяя возможности лечения». 2016; 8.
- Paik P.K., Drilon A., Fan P.D. et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015; 5: 842-9.
